Benzimidazole-based compounds kill Mycobacterium tuberculosis

Yaling Gong,Selin Somersan Karakaya,Xiaoyong Guo,Purong Zheng,Ben Gold,Yao Ma,David Little,Julia Roberts,Thulasi Warrier,Xiuju Jiang,Maneesh Pingle,Carl F. Nathan,Gang Liu
DOI: https://doi.org/10.1016/j.ejmech.2014.01.039
IF: 7.088
2014-01-01
European Journal of Medicinal Chemistry
Abstract:Tuberculosis remains one of the deadliest infectious diseases, killing 1.4 million people annually and showing a rapid increase in cases resistant to multiple drugs. New antibiotics against tuberculosis are urgently needed. Here we describe the design, synthesis and structure–activity relationships of a series of benzimidazole-based compounds with activity against Mycobacterium tuberculosis (Mtb) in a replicating state, a physiologically-induced non-replicating state, or both. Compounds 49, 67, 68, 69, 70, and 72, which shared a 5-nitrofuranyl moiety, exhibited high potency and acceptable selectivity indices (SI). As illustrated by compound 70 (MIC90 < 0.049 μg/mL, SI > 512), the 5-nitrofuranyl group was compatible with minimal cytotoxicity and good intra-macrophage killing, although it lacked non-replicating activity when assessed by CFU assays. Compound 70 had low mutagenic potential by SOS Chromotest assay, making this class of compounds good candidates for further evaluation and target identification.
What problem does this paper attempt to address?